Common questions, in one place.

A 45–60 minute consultation with Dr. Glowney. We review your history and imaging, perform a focused physical exam, and walk through which therapies (if any) are appropriate for your situation. You leave with a clear plan, not a sales pitch.

Dr. Jason Glowney performs every aspiration, injection, and image-guided delivery personally. He does not delegate procedures to a PA or RN. Lab processing is performed in our on-site biologics lab by trained clinic staff under his oversight.

A standard orthopedic visit typically ends in one of three places: physical therapy, a cortisone injection, or a surgical referral. We add a fourth path, autologous biologic therapy, and we tell you honestly when one of the first three is the better answer for your case.

Candidacy depends on your imaging, condition stage, and overall health. Mild-to-moderate joint and tendon conditions respond best. Advanced, diffuse arthritis typically does not: in those cases we'll tell you, and refer you to the right specialist instead.

(1) Request a consultation by phone, web form, or email: we follow up within one business day. (2) Send any recent imaging (MRI, X-ray) so Dr. Glowney can review it before your visit. (3) Come in for an unhurried conversation about whether biologics fit your goals.

PRP uses concentrated platelets and growth factors from your blood. BMAC uses mesenchymal stromal cell–containing material from your own bone marrow. Consistent with FDA guidance, we don't use the colloquial "stem cell therapy" framing: every therapy we offer is autologous (your own cells, minimally manipulated), not donor-derived or culture-expanded.

Biological response varies by patient and condition. Many patients note progressive improvement over 4–12 weeks. We schedule functional follow-up at 6 and 12 weeks to track progress objectively, and reassess at 12–16 weeks if meaningful response hasn't emerged.

Yes. Dr. Glowney founded the Boulder Biologics Research Center (formerly Apeiron Research Center), our non-profit sister organization, which runs IRB-approved trials investigating cellular therapies for orthopedic and systemic conditions. Eligible patients are offered enrollment when a study fits their situation.

PRP is prepared from your own blood using a controlled, multi-step laboratory process: venous draw into anticoagulated tubes, a low-force "soft spin" to separate plasma from red cells, a higher-force "hard spin" to concentrate platelets into a pellet, and resuspension to an indication-specific platelet concentration. Baseline CBC and post-processing analysis are documented for every preparation. Our protocols follow published reporting frameworks (PAW, DEPA).

Most patients experience mild-to-moderate discomfort during the injection itself. Anatomic location and underlying condition affect this. Non-acidic, non-platelet-toxic local anesthetics are used for comfort, and ultrasound or fluoroscopic guidance reduces unnecessary needle passes.

PRP can be clinically helpful for selected musculoskeletal conditions, but effectiveness is variable. PRP is not a single standardized product, and outcomes are influenced by diagnosis, disease severity, formulation, delivery technique, rehabilitation, and individual patient biology.

Evidence is strongest for knee osteoarthritis, lateral epicondylitis (tennis elbow), and rotator cuff tendinopathy. Improvement is usually gradual, often emerging over 4–12 weeks.

The amount varies by patient and indication, number of sites, severity, baseline platelet count, target concentration. Volumes are generally comparable to, and often less than, those drawn for routine laboratory testing. Collection uses sterile technique and you're monitored throughout.

In selected cases, yes, but this is an individualized decision. Considerations include total PRP volume, recovery profile across sites, and whether the indications share a similar formulation. Dr. Glowney makes the call during your evaluation.

Yes. PRP uses only local anesthesia, so you can drive yourself to and from the appointment. If the treated site is in a lower limb where soreness might affect pedal control, let us know in advance and we'll plan accordingly.

We recommend avoiding NSAIDs in the early window after PRP. Inhibiting the inflammatory cascade right after the injection may blunt the very biologic response we're trying to support. Acetaminophen, ice, and elevation are acceptable for discomfort within the first few days.

Avoid strenuous activity for the first 24–48 hours. After that, return gradually to your rehabilitation program as outlined in your post-procedure plan. Progressive, condition-specific loading is part of how PRP outcomes are optimized, especially for tendinopathy.

• Protocol-driven, not kit-based: platelet concentration is adjusted to indication and your individual baseline.
• On-site, same-day processing: no shipping, no storage delays.
• Two-spin density-gradient preparation with controlled centrifugation forces.
• Leukocyte and RBC content tailored to indication rather than a one-size-fits-all formulation.
• Image-guided delivery on every procedure.
• Documentation of every preparation: baseline CBC and post-processing analysis.

A solution of hypertonic dextrose (a medical-grade sugar solution at concentrations above physiologic levels) mixed with saline. A local anesthetic may be added for comfort. It is not a biologic: there are no cells or growth factors in the syringe.

PRP is autologous and biologic, concentrated platelets and growth factors from your blood. Prolotherapy is non-biologic, the dextrose acts as a local irritant that stimulates an inflammatory response, theoretically promoting collagen synthesis at the injection site. Different mechanisms, often different indications.

Improvement, when it occurs, is typically gradual and often requires a series of injections spaced over weeks to months. The exact cadence depends on the structure being treated and your response. Most protocols involve 3–6 sessions, with reassessment between.

Most patients tolerate prolotherapy well, especially with local anesthesia. Mild-to-moderate soreness for several days after the injection is common, and is part of the intended inflammatory response.

Most patients can resume light activity the same day. We recommend avoiding strenuous activity for 24–72 hours, then a gradual return as guided by your post-procedure plan and any concurrent rehabilitation.

Prolotherapy is generally not covered by commercial insurance plans or Medicare for musculoskeletal indications. We discuss expected costs in advance and supply HSA/FSA reimbursement documentation where applicable.

Annual physicals are designed to screen for current disease. A longevity assessment quantifies your biological age, your trajectory across multiple systems (epigenetic, cardiometabolic, neurocognitive, mitochondrial), and the modifiable drivers, then builds a personalized plan to change that trajectory before disease emerges.

Yes, when clinically appropriate. HRT decisions follow individual assessment of hormone metabolism, cardiovascular risk, family history, and patient goals, with ongoing monitoring and documentation. We do not prescribe hormones without a complete workup and follow-up cadence.

We discuss peptide options where the evidence base and regulatory status support their use. We do not promote unregulated or research-only compounds for general "optimization."

Most clients begin with a comprehensive assessment, followed by 3–6 months of active optimization with quarterly follow-up. Long-term care is structured around an annual cadence with interval testing.

Standard labs may be covered by insurance. Specialty testing (epigenetic clocks, advanced metabolics) and longevity consultations are typically not covered. We provide transparent pricing during your initial conversation and supply HSA/FSA documentation where applicable.

Yes, and many of our patients do. There's real synergy: musculoskeletal function is a longevity variable, and biologic strategies often appear in both pathways.